Subscribe →
← All content Health & Medicine

FDA's Controversial Decision on MDMA for PTSD Treatment

Jun 5, 2024 · 18K views · 2K likes · 86 comments · 134 shares

Video link

AI Search Summary

This June 2024 science-news video explains why an FDA advisory committee voted against recommending MDMA-assisted therapy for PTSD despite promising phase 3 trial results. The page covers the clinical-trial symptom reductions, the difficulty of placebo controls for psychoactive drugs, safety and study-design concerns, therapist-misconduct concerns, and participant testimony from Cristina Pearse.

  • Main question: Why did the FDA Advisory Committee vote against MDMA-assisted therapy for PTSD?
  • Short answer / core takeaway: The committee was not convinced the submitted evidence adequately proved effectiveness and safety, especially given unblinding/placebo issues, safety-data limitations, dropout rates, study diversity concerns, abuse-potential reporting, and therapy-standardization problems.
  • Evidence type: FDA advisory-committee news analysis, phase 3 clinical trials, ICER report, FDA briefing materials, and patient testimony.
  • Search topics: MDMA PTSD FDA advisory committee, MDMA-assisted therapy placebo problem, Lykos PTSD trial, psychedelic therapy safety, PTSD treatment clinical trial.

Common Search Questions

What did the FDA advisory committee vote on?

The committee voted on whether the evidence showed MDMA-assisted therapy was effective for PTSD and whether the benefits outweighed the risks. The video says the committee voted 9 to 2 against effectiveness and 10 to 1 that the risks outweighed the benefits.

Why was placebo control such a problem?

MDMA has noticeable psychoactive effects, so participants and therapists may be able to tell whether someone received MDMA or placebo. That makes it harder to separate the drug’s biological effect from expectancy effects and therapy context.

What safety concerns were raised?

The transcript lists concerns about heart and liver safety data, dropout rates, lack of diversity, abuse-potential reporting, pleasurable experiences, and a case of improper physical touching by therapists.

Did the trials show improvement?

The transcript says the submitted trials showed large symptom reductions, with many participants no longer meeting PTSD diagnostic criteria. The dispute was whether the submitted evidence and study design were strong enough for approval.

What makes MDMA-assisted therapy hard to regulate?

The video notes that the FDA had not previously regulated a combination of drug plus talk therapy. Standardizing the therapy component is difficult because outcomes can depend on clinician behavior and skill.

Key Takeaways

  • The video covers the advisory-committee vote, not a full timeless summary of MDMA’s current regulatory status.
  • Trial results looked promising, but the committee had major concerns about bias, safety, and implementation.
  • Psychoactive drugs create unusually hard placebo and blinding problems.
  • Therapy standardization and therapist ethics are central safety issues for psychedelic-assisted therapy.
  • The caption’s source list belongs in References, not Additional Notes.

Transcript

The advisory-committee decision

Yesterday, the FDA Advisory Committee voted against approving MDMA, aka ecstasy or molly, for treating PTSD when combined with psychotherapy.

The two clinical trials submitted as evidence showed that it worked really well, with around 80% showing a large reduction in symptoms and about three quarters getting to the point where they no longer qualified as having PTSD, after having severe PTSD for around 15 years.

The creator introduces a clip from one of the participants that moved him.

Why PTSD treatment stakes are high

Around 13 million people in the US alone suffer from PTSD. Close to 2,000 suicides per year are attributed to it, and it costs the US economy over $200 billion per year.

It had been 25 years since the FDA approved any new treatment for PTSD. So why did the FDA say no here?

The meeting and votes

The meeting lasted 8 hours and included over 30 speakers, including scientists who had studied MDMA for years and clinical trial participants.

The first vote asked whether MDMA was effective for treating PTSD. The committee voted 9 to 2 in favor of it not being effective.

The second vote asked whether the risks outweighed the benefits. The committee voted 10 to 1 that it was too risky.

Effectiveness and placebo concerns

The biggest concern for effectiveness was that it is very hard to have a good placebo for a drug like MDMA. When you take it, you know.

The studies measured PTSD severity on an 80-point scale where higher scores mean more severe symptoms. They included three sessions over 18 weeks with psychotherapy plus placebo or psychotherapy plus MDMA.

By the end of the studies, the therapy group improved by around 14 points. The therapy plus MDMA group improved by 24 points, and the effect lasted at least six months out.

But the concern was that some of the effect may have come from participants feeling the MDMA and believing it would help, rather than from a specific chemical effect on PTSD.

Safety, conduct, and study-design concerns

There were also concerns about insufficient safety data for effects on the heart and liver, a high dropout rate of around one in four by month six, lack of study diversity, and lack of reporting about pleasurable MDMA experiences and abuse potential.

The transcript also mentions one case of improper physical touching by therapists, one of whom was unlicensed.

Why drug-plus-therapy is hard to regulate

This process is harder because the FDA had never had to regulate a combination drug plus talk therapy before.

You do not want to just give the drug, but it is very hard to standardize the therapy. Outcomes are affected by human behavior and clinician skill.

The creator’s interpretation

The creator says there is still hope because this was an advisory committee and the FDA final decision would come later.

He says the vote felt less like a conclusion that MDMA could not work and more like a conclusion that the company did not do a good enough job with study design and the overall submission.

More scientific rigor is needed to quantify and standardize the treatment so it can be as safe and effective as possible before being released more broadly.

Cristina Pearse testimony

The video closes with a clip from clinical trial participant Cristina Pearse, who described decades of PTSD symptoms, multiple diagnoses, medications, suicidality, alcohol self-medication, and the effects of MDMA-assisted therapy.

She testified that MDMA-assisted therapy saved her life, helped her process trauma with skilled therapists, and left her no longer needing the medication or alcohol she had relied on.

Additional Notes

Caption context

The caption describes the advisory-committee vote as surprising and asks viewers to comment with thoughts on MDMA’s potential or experiences with PTSD treatments.

It asks viewers to watch Cristina Pearse’s testimony from the clinical trial at the FDA meeting and includes newsletter/background copy about Distilled Science.

Time-bound context

This page preserves the June 2024 advisory-committee discussion. Later FDA actions and later evidence updates should be checked separately if using this page for current regulatory status.

Keywords and topics

  • MDMA-assisted therapy
  • PTSD treatment
  • FDA advisory committee
  • Psychedelic therapy
  • Placebo and blinding
  • Therapy standardization

References